Keywords: new, phase, ii, data, merck, co, crixivan
New Phase II Data On Merck & Co's Crixivan
Article | 09 October 1995
Merck & Co's protease inhibitor Crixivan (indinavir) can reduce viral load by 99%, compared to 40% with Glaxo Wellcome's zidovudine, according to a 73 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
